Economic information and modeling reportBudget impact model
Approach and framework
4 evidence topics · 7 sources
Budget impact model of cretostimogene grenadenorepvec: approach and framework
No evidence found.
Good-practice framework for budget impact analysis
“The key elements of a BIA include estimating the size of the eligible population, the current mix of treatments and the expected mix after the introduction of the new intervention, the cost of the treatment mixes, and any changes expected in condition-related costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Where possible, the BIA calculations should be performed by using a simple cost calculator approach because of its ease of use for budget holders.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, the Task Force recommends that the analyst use the simplest design that will generate credible and transparent estimates.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The model should be consistent with that used for the CEA with regard to clinical and economic assumptions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Structure of a published budget impact model of nadofaragene firadenovec
Potential budget impact method of the ICER review
Model structures of published cost-effectiveness and cost-per-responder analyses
“A Markov decision analytic model was created using TreeAge Pro software (TreeAge Software, Inc, Williamstown, Massachusetts).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Each treatment option modelled as a Markov node with health states including surveillance, treatment toxicity, recurrence, progression to MIBC, metastasis, and death (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We developed a de novo semi-Markov decision analytic model with model structure and inputs informed by key clinical trials, previous economic models, systematic literature reviews, and input from stakeholders (patients, advocacy groups, clinicians, payers, researchers, and manufacturers).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote